UnknownNot Applicable

Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis

Spain50 participantsStarted 2014-04

Plain-language summary

The purpose of this study is to demonstrate that 1) the secretion of mucins, antimicrobial peptides and Toll-like receptors is altered in certain patients with non-CF bronchiectasis, which makes them more susceptible to be infected by potentially pathogenic bacteria (PPB); and 2) the electronic nose is able to detect patterns of specific Volatile Organic Compounds (VOC) for patients with non-CF bronchiectasis colonized by PPB.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of non- CF bronchiectasis based on at least 1 lobe with bronchial dilatation and compatible clinical symptoms such as cough, sputum production and respiratory infections. * Signed informed consent. Exclusion Criteria: * Presence of exacerbation in the last 4 weeks. * Antibiotic treatment in the last 4 weeks * Use of oral corticosteroids in the last 4 weeks * Concomitant terminal illness. * Current cigarette smoking * Active allergic bronchopulmonary aspergillosis * Diagnosis of tuberculosis or active non-tuberculous Mycobacterial infection

What they're measuring

Change from baseline in sputum mucin levels at 12 months

Timeframe: Baseline and 12 months

Trial details

NCT IDNCT02163642

SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-04

Contact for this trial

Oriol Sibila, MD PhD

0034647914193 osibila@santpau.cat

View on ClinicalTrials.gov More Bronchiectasis trials